Anti-infective Agents Market Size, Share, Growth Analysis, By Type (Revenue, USD Billion; 2013 - 2026)(Antibacterial, Antiviral), By Antibacterial Drug Class (Revenue, USD Billion, 2013 - 2026)(Cephalosporins, Penicillin), By Antibacterial Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Antifungal Drug Class (Revenue, USD Billion, 2013 - 2026)(Azoles, Echinocandins), By Antifungal Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Antiviral Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Route of Administration (Revenue, USD Billion, 2013 - 2026)(Topical, Oral), By Distribution Channel (Revenue, USD Billion, 2013 - 2026)(Hospital Pharmacies, Retail Pharmacies), By Regional (Revenue, USD Billion; 2013 - 2026)(North America, The U.S.) - Industry Forecast 2024-2031

The market for Anti-infective Agents was estimated to be valued at US$ XX Mn in 2021.

The Anti-infective Agents Market is estimated to grow at a CAGR of XX% by 2028.

The Anti-infective Agents Market is segmented on the basis of Type (Revenue, USD Billion; 2013 - 2026), Antibacterial Drug Class (Revenue, USD Billion, 2013 - 2026), Antibacterial Route of Administration (Revenue, USD Billion, 2013 - 2026), Antifungal Drug Class (Revenue, USD Billion, 2013 - 2026), Antifungal Route of Administration (Revenue, USD Billion, 2013 - 2026), Antiviral Route of Administration (Revenue, USD Billion, 2013 - 2026), Route of Administration (Revenue, USD Billion, 2013 - 2026), Distribution Channel (Revenue, USD Billion, 2013 - 2026), Regional (Revenue, USD Billion; 2013 - 2026).

Based on region, the Anti-infective Agents Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Anti-infective Agents Market are , GlaxoSmithKline plc. , Pfizer Inc. , Bayer AG; Sanofi , Merck & Co., Inc. , Bristol-Myers Squibb Company , Abbott , Novartis AG , Johnson & Johnson Services Inc. , Gilead Sciences, Inc. , Astellas Pharma Inc.".